Volitionrx Ltd (VNRX) 4.4500 $VNRX
VolitionRx NuQ(R) Blood Test Detects 84% of Colorectal Cancers; Including Both Early- and Later-stage Cancers
PR Newswire - Thu Sep 11, 7:00AM CDT
VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types, today announced that CEO Cameron Reynolds will this morning present topline data from its 4,800-subject colorectal cancer trial at Hvidovre Hospital, Copenhagen, Denmark. Mr. Reynolds will present data from an initial representative 938-subject sample, demonstrating that the Company is able to correctly diagnose 84% of colorectal cancers, including early-stage cancers, using its NuQ® blood-based diagnostic platform.
VolitionRx to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
PR Newswire - Fri Sep 05, 5:30AM CDT
VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types, today announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to present at the Aegis Capital 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at Wynn Hotel in Las Vegas, NV.
VolitionRx Invests in Laboratory Automation System to Increase Throughput Capacity for Large Clinical Trials
PR Newswire - Wed Aug 13, 5:30AM CDT
VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced it has installed a Tecan EVO200 automated liquid handling system in its Namur, Belgium laboratory. The Tecan EVO200 is a robot that will significantly accelerate VolitionRx's large scale clinical studies by increasing the throughput and rate of blood sample analysis by up to five times that of the current manual methods. Initially the robot will be used in a stand-alone mode but Volition is in the process of establishing a Laboratory Information Management System (LIMS) which will integrate the robot into a wider laboratory automation system. This will provide a seamless workflow incorporating blood sample recognition, testing, data capture, and quality control as part of a quality management system.
VolitionRx Announces New Chief Financial Officer
PR Newswire - Tue Jul 01, 5:30AM CDT
VolitionRx Limited (OTCQB: VNRX), a life sciences company, today announces the appointment of a new Chief Financial Officer (CFO), Mike O'Connell. Mr. O'Connell will take on this key role as VolitionRx works towards securing a listing on a senior US stock exchange.
VolitionRx Sells First NuQ® Research Use Only Kits to Active Motif
PR Newswire - Mon Jun 23, 5:30AM CDT
VolitionRx Limited (OTCQB: VNRX), a life sciences company, today announces its first wholesale order of NuQ® Research Use Only kits to Active Motif. Each kit allows epigenetics researchers to identify and analyze a different nucleosome structure. Active Motif will distribute the kits in its key markets of Europe, the United States and Japan.
CalNaturale Svelte® Shares Tips For Discovering A Healthier You In 2014
PR Newswire - Thu Jan 09, 2:54PM CST
To ring in the New Year and help make health and fitness resolutions stick through the winter and beyond, CalNaturale Svelte®, the premium line of USDA Certified organic protein shakes that provides great taste, sustained nutrition and energy through pure and simple ingredients, is offering simple ways for people to stay "Svelte" this season. Known for its positive, on-package affirmations like "Hello Beautiful(TM)" and "Looking Good(TM)," the company aims to help individuals looking to achieve new health goals in 2014 and look and feel their best.
CEGA Welcomes Jimmy Delshad to Board of Directors
PR Newswire - Wed Dec 18, 6:00AM CST
Concurrent with the launch of the CEGA Solar Fund LP, CEGAlliance Inc. is pleased to welcome the Honorable Jimmy Delshad, former Mayor of Beverly Hills, California, as its Vice Chairman of its Board of Directors. This well-timed addition brings high potential to the CEGA Solar Fund LP, through Delshad's prestigious reputation.
VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant
PR Newswire - Tue Sep 03, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, is lead partner of a consortium in a project valued at EUR 779,493 (approx. US$1M) under the EUREKA Eurostars scheme. The project aims to develop new applications of the Nucleosomics biomarker technology in inflammatory disease. The research will build on VolitionRx's ongoing cancer diagnostic research program.
VolitionRx to use Innova Biosciences' Biotin Technology in its Epigenetic Research Kits
PR Newswire - Mon Jul 22, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on the development of blood-based diagnostic tests, has signed a non-exclusive in-licensing agreement with Innova Biosciences, a specialist provider of bioconjugation systems, based in Cambridge, UK. Under the agreement, Innova Biosciences will supply its Lightning-Link® Biotin technology for Volition's NuQ® epigenetic profiling research kits. The addition of the Lightning-Link technology will help Volition to improve the accuracy of its test, whilst speeding up production of the research kits.
VolitionRx Embarks on Colorectal Cancer Trial with Hvidovre Hospital, Denmark
PR Newswire - Wed May 29, 5:30AM CDT
VolitionRx Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, announces that it has signed an agreement with Hvidovre Hospital, University of Copenhagen, Denmark, for two colorectal cancer (CRC) clinical trials. The trials will analyze blood samples from approximately 10,800 patients, using VolitionRx's proprietary NuQ® tests.
Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-Stage Cancer Diagnostic
PR Newswire - Wed May 01, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company that is developing blood-based diagnostic tests for different types of cancer, has retained Racepoint Group as its public relations agency of record. The company's tests are based on the science of Nucleosomics® which is the practice of identifying and measuring nucleosomes in the bloodstream - an indication that cancer is present.
VolitionRx Files Two Patent Applications
PR Newswire - Thu Apr 04, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has filed two new patent applications. The first patent application is an extension to the Nucleosomics® technology for the detection of histone modifications in nucleosomes; the second covers the use of Volition's Nucleosomics® technology in personalized medicine as a predictor of the efficacy of cancer treatment.
VolitionRx Hires Head of US Operations, Jason Terrell MD
PR Newswire - Tue Mar 26, 6:00AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has hired Jason Terrell MD as Head of US Operations. Dr Terrell will initially be responsible for facilitating Volition's entry into the US market, acting as the company's FDA liaison and pursuing and negotiating FDA compliant US clinical trials.
VolitionRx NuQ(R) Blood Test Detects 84% of Colorectal Cancers; Including Both Early- and Later-stage Cancers
PR Newswire - Thu Sep 11, 7:00AM CDT
VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types, today announced that CEO Cameron Reynolds will this morning present topline data from its 4,800-subject colorectal cancer trial at Hvidovre Hospital, Copenhagen, Denmark. Mr. Reynolds will present data from an initial representative 938-subject sample, demonstrating that the Company is able to correctly diagnose 84% of colorectal cancers, including early-stage cancers, using its NuQ® blood-based diagnostic platform.
VolitionRx to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
PR Newswire - Fri Sep 05, 5:30AM CDT
VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types, today announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to present at the Aegis Capital 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at Wynn Hotel in Las Vegas, NV.
VolitionRx Invests in Laboratory Automation System to Increase Throughput Capacity for Large Clinical Trials
PR Newswire - Wed Aug 13, 5:30AM CDT
VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced it has installed a Tecan EVO200 automated liquid handling system in its Namur, Belgium laboratory. The Tecan EVO200 is a robot that will significantly accelerate VolitionRx's large scale clinical studies by increasing the throughput and rate of blood sample analysis by up to five times that of the current manual methods. Initially the robot will be used in a stand-alone mode but Volition is in the process of establishing a Laboratory Information Management System (LIMS) which will integrate the robot into a wider laboratory automation system. This will provide a seamless workflow incorporating blood sample recognition, testing, data capture, and quality control as part of a quality management system.
VolitionRx Announces New Chief Financial Officer
PR Newswire - Tue Jul 01, 5:30AM CDT
VolitionRx Limited (OTCQB: VNRX), a life sciences company, today announces the appointment of a new Chief Financial Officer (CFO), Mike O'Connell. Mr. O'Connell will take on this key role as VolitionRx works towards securing a listing on a senior US stock exchange.
VolitionRx Sells First NuQ® Research Use Only Kits to Active Motif
PR Newswire - Mon Jun 23, 5:30AM CDT
VolitionRx Limited (OTCQB: VNRX), a life sciences company, today announces its first wholesale order of NuQ® Research Use Only kits to Active Motif. Each kit allows epigenetics researchers to identify and analyze a different nucleosome structure. Active Motif will distribute the kits in its key markets of Europe, the United States and Japan.
CalNaturale Svelte® Shares Tips For Discovering A Healthier You In 2014
PR Newswire - Thu Jan 09, 2:54PM CST
To ring in the New Year and help make health and fitness resolutions stick through the winter and beyond, CalNaturale Svelte®, the premium line of USDA Certified organic protein shakes that provides great taste, sustained nutrition and energy through pure and simple ingredients, is offering simple ways for people to stay "Svelte" this season. Known for its positive, on-package affirmations like "Hello Beautiful(TM)" and "Looking Good(TM)," the company aims to help individuals looking to achieve new health goals in 2014 and look and feel their best.
CEGA Welcomes Jimmy Delshad to Board of Directors
PR Newswire - Wed Dec 18, 6:00AM CST
Concurrent with the launch of the CEGA Solar Fund LP, CEGAlliance Inc. is pleased to welcome the Honorable Jimmy Delshad, former Mayor of Beverly Hills, California, as its Vice Chairman of its Board of Directors. This well-timed addition brings high potential to the CEGA Solar Fund LP, through Delshad's prestigious reputation.
VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant
PR Newswire - Tue Sep 03, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, is lead partner of a consortium in a project valued at EUR 779,493 (approx. US$1M) under the EUREKA Eurostars scheme. The project aims to develop new applications of the Nucleosomics biomarker technology in inflammatory disease. The research will build on VolitionRx's ongoing cancer diagnostic research program.
VolitionRx to use Innova Biosciences' Biotin Technology in its Epigenetic Research Kits
PR Newswire - Mon Jul 22, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on the development of blood-based diagnostic tests, has signed a non-exclusive in-licensing agreement with Innova Biosciences, a specialist provider of bioconjugation systems, based in Cambridge, UK. Under the agreement, Innova Biosciences will supply its Lightning-Link® Biotin technology for Volition's NuQ® epigenetic profiling research kits. The addition of the Lightning-Link technology will help Volition to improve the accuracy of its test, whilst speeding up production of the research kits.
VolitionRx Embarks on Colorectal Cancer Trial with Hvidovre Hospital, Denmark
PR Newswire - Wed May 29, 5:30AM CDT
VolitionRx Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, announces that it has signed an agreement with Hvidovre Hospital, University of Copenhagen, Denmark, for two colorectal cancer (CRC) clinical trials. The trials will analyze blood samples from approximately 10,800 patients, using VolitionRx's proprietary NuQ® tests.
Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-Stage Cancer Diagnostic
PR Newswire - Wed May 01, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company that is developing blood-based diagnostic tests for different types of cancer, has retained Racepoint Group as its public relations agency of record. The company's tests are based on the science of Nucleosomics® which is the practice of identifying and measuring nucleosomes in the bloodstream - an indication that cancer is present.
VolitionRx Files Two Patent Applications
PR Newswire - Thu Apr 04, 5:30AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has filed two new patent applications. The first patent application is an extension to the Nucleosomics® technology for the detection of histone modifications in nucleosomes; the second covers the use of Volition's Nucleosomics® technology in personalized medicine as a predictor of the efficacy of cancer treatment.
VolitionRx Hires Head of US Operations, Jason Terrell MD
PR Newswire - Tue Mar 26, 6:00AM CDT
VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has hired Jason Terrell MD as Head of US Operations. Dr Terrell will initially be responsible for facilitating Volition's entry into the US market, acting as the company's FDA liaison and pursuing and negotiating FDA compliant US clinical trials.
